Sign Up
OverviewAPI
RSV vaccines from Pfizer and GSK for older adults may be linked to a higher risk of Guillain-Barré syndrome (GBS), based on data showing elevated GBS rates post-vaccination. The FDA noted an overrepresentation of GBS cases with Pfizer's Abrysvo. Despite uncertainties, CDC supports RSV vaccines' use in individuals over 60, with ongoing safety monitoring by both companies.

Ask a question